BackNovo Nordisk A/S Class B Overview

Novo Nordisk A/S Class B Other Current Assets

Novo Nordisk A/S Class B's other current assets is $3.9B.

Get informed when a big investor buys or sells

+ Follow
Other Current Assets
$3.85B
68.64% YoYΔ $-8.43B vs prior year quarter

Peer average / median

Loading

Novo Nordisk A/S Class B Other Current Assets History

Loading

Novo Nordisk A/S Class B vs. peers: Other Current Assets Comparison

Loading

Novo Nordisk A/S Class B Other Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Novo Nordisk A/S Class B (NONOF) FAQ

The latest other current assets for NONOF is $3.9B as of June 2026. That compares with $12B in the prior-year period — down 68.6% year over year. Investors often review this figure alongside Novo Nordisk A/S Class B's historical trend and sector peers before judging valuation or financial health.

Over the past year, NONOF's other current assets moved from $12B to $3.9B — a 68.6% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Novo Nordisk A/S Class B's operating scale or balance-sheet position.

A other current assets figure of $3.9B for NONOF is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting NONOF's other current assets ($3.9B), review year-over-year change from $12B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Novo Nordisk A/S Class B's other current assets against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.